#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Stroke is a major cause of dementia , especially in the elderly .
2-1	16-22	Stroke	abstract	new	coref	2-3[3_0]
2-2	23-25	is	_	_	_	_
2-3	26-27	a	abstract[3]	giv[3]	coref	20-17[134_3]
2-4	28-33	major	abstract[3]	giv[3]	_	_
2-5	34-39	cause	abstract[3]	giv[3]	_	_
2-6	40-42	of	abstract[3]	giv[3]	_	_
2-7	43-51	dementia	abstract[3]|abstract	giv[3]|new	coref	3-3[5_0]
2-8	52-53	,	abstract[3]	giv[3]	_	_
2-9	54-64	especially	abstract[3]	giv[3]	_	_
2-10	65-67	in	abstract[3]	giv[3]	_	_
2-11	68-71	the	abstract[3]	giv[3]	_	_
2-12	72-79	elderly	abstract[3]	giv[3]	_	_
2-13	80-81	.	_	_	_	_

#Text=Specifically , the one-year post-stroke dementia ( PSD ) rates after first-ever and recurrent stroke are approximately 10 % and 30 % , respectively .
3-1	82-94	Specifically	_	_	_	_
3-2	95-96	,	_	_	_	_
3-3	97-100	the	abstract[5]	giv[5]	coref	4-4[12_5]
3-4	101-109	one-year	abstract[5]	giv[5]	_	_
3-5	110-121	post-stroke	abstract[5]	giv[5]	_	_
3-6	122-130	dementia	abstract[5]	giv[5]	_	_
3-7	131-132	(	_	_	_	_
3-8	133-136	PSD	abstract	new	_	_
3-9	137-138	)	_	_	_	_
3-10	139-144	rates	_	_	_	_
3-11	145-150	after	_	_	_	_
3-12	151-161	first-ever	event[7]	new[7]	coref	10-31[0_7]
3-13	162-165	and	event[7]	new[7]	_	_
3-14	166-175	recurrent	event[7]	new[7]	_	_
3-15	176-182	stroke	event[7]	new[7]	_	_
3-16	183-186	are	_	_	_	_
3-17	187-200	approximately	quantity[8]	new[8]	_	_
3-18	201-203	10	quantity[8]	new[8]	_	_
3-19	204-205	%	quantity[8]	new[8]	_	_
3-20	206-209	and	_	_	_	_
3-21	210-212	30	quantity[9]	new[9]	_	_
3-22	213-214	%	quantity[9]	new[9]	_	_
3-23	215-216	,	_	_	_	_
3-24	217-229	respectively	_	_	_	_
3-25	230-231	.	_	_	_	_

#Text=Neuropathological studies into Alzheimer ’s disease ( AD ) have shown that AD pathology is often concomitant with ischemic lesions in the elderly .
4-1	232-249	Neuropathological	event[10]	new[10]	coref	23-31[158_10]
4-2	250-257	studies	event[10]	new[10]	_	_
4-3	258-262	into	event[10]	new[10]	_	_
4-4	263-272	Alzheimer	event[10]|person[11]|abstract[12]	new[10]|new[11]|giv[12]	appos	4-8[0_12]
4-5	273-275	’s	event[10]|person[11]|abstract[12]	new[10]|new[11]|giv[12]	_	_
4-6	276-283	disease	event[10]|abstract[12]	new[10]|giv[12]	_	_
4-7	284-285	(	_	_	_	_
4-8	286-288	AD	abstract	giv	coref	4-13
4-9	289-290	)	_	_	_	_
4-10	291-295	have	_	_	_	_
4-11	296-301	shown	_	_	_	_
4-12	302-306	that	_	_	_	_
4-13	307-309	AD	abstract|abstract[15]	giv|new[15]	coref|coref	5-35|6-11[34_15]
4-14	310-319	pathology	abstract[15]	new[15]	_	_
4-15	320-322	is	_	_	_	_
4-16	323-328	often	_	_	_	_
4-17	329-340	concomitant	_	_	_	_
4-18	341-345	with	_	_	_	_
4-19	346-354	ischemic	object|abstract[17]	new|new[17]	coref	18-30[116_0]
4-20	355-362	lesions	abstract[17]	new[17]	_	_
4-21	363-365	in	_	_	_	_
4-22	366-369	the	_	_	_	_
4-23	370-377	elderly	_	_	_	_
4-24	378-379	.	_	_	_	_

#Text=For instance , evidence from the Nun Study showed that lacunes increase the risk of clinical expression of cognitive impairment more than 20 times during early Braak stages that were yet sufficient to produce dementia symptoms .
5-1	380-383	For	_	_	_	_
5-2	384-392	instance	_	_	_	_
5-3	393-394	,	_	_	_	_
5-4	395-403	evidence	abstract[18]	new[18]	_	_
5-5	404-408	from	abstract[18]	new[18]	_	_
5-6	409-412	the	abstract[18]|abstract[20]	new[18]|new[20]	coref	18-1[106_20]
5-7	413-416	Nun	abstract[18]|person|abstract[20]	new[18]|new|new[20]	_	_
5-8	417-422	Study	abstract[18]|abstract[20]	new[18]|new[20]	_	_
5-9	423-429	showed	_	_	_	_
5-10	430-434	that	_	_	_	_
5-11	435-442	lacunes	abstract	new	_	_
5-12	443-451	increase	_	_	_	_
5-13	452-455	the	abstract[22]	new[22]	coref	21-9[139_22]
5-14	456-460	risk	abstract[22]	new[22]	_	_
5-15	461-463	of	abstract[22]	new[22]	_	_
5-16	464-472	clinical	abstract[22]|abstract[23]	new[22]|new[23]	_	_
5-17	473-483	expression	abstract[22]|abstract[23]	new[22]|new[23]	_	_
5-18	484-486	of	abstract[22]|abstract[23]	new[22]|new[23]	_	_
5-19	487-496	cognitive	abstract[22]|abstract[23]|abstract[24]	new[22]|new[23]|new[24]	ana	6-1[0_24]
5-20	497-507	impairment	abstract[22]|abstract[23]|abstract[24]	new[22]|new[23]|new[24]	_	_
5-21	508-512	more	abstract[22]|abstract[23]|abstract[24]|time[25]	new[22]|new[23]|new[24]|new[25]	_	_
5-22	513-517	than	abstract[22]|abstract[23]|abstract[24]|time[25]	new[22]|new[23]|new[24]|new[25]	_	_
5-23	518-520	20	abstract[22]|abstract[23]|abstract[24]|time[25]	new[22]|new[23]|new[24]|new[25]	_	_
5-24	521-526	times	abstract[22]|abstract[23]|abstract[24]|time[25]	new[22]|new[23]|new[24]|new[25]	_	_
5-25	527-533	during	_	_	_	_
5-26	534-539	early	abstract[27]	new[27]	_	_
5-27	540-545	Braak	abstract|abstract[27]	new|new[27]	_	_
5-28	546-552	stages	abstract[27]	new[27]	_	_
5-29	553-557	that	_	_	_	_
5-30	558-562	were	_	_	_	_
5-31	563-566	yet	_	_	_	_
5-32	567-577	sufficient	_	_	_	_
5-33	578-580	to	_	_	_	_
5-34	581-588	produce	_	_	_	_
5-35	589-597	dementia	abstract|abstract[29]	giv|new[29]	coref	6-11
5-36	598-606	symptoms	abstract[29]	new[29]	_	_
5-37	607-608	.	_	_	_	_

#Text=It follows that vascular insults enhance the clinical expression of AD pathology .
6-1	609-611	It	abstract	giv	coref	13-11[81_0]
6-2	612-619	follows	_	_	_	_
6-3	620-624	that	_	_	_	_
6-4	625-633	vascular	abstract[31]	new[31]	_	_
6-5	634-641	insults	abstract[31]	new[31]	_	_
6-6	642-649	enhance	_	_	_	_
6-7	650-653	the	abstract[32]	new[32]	_	_
6-8	654-662	clinical	abstract[32]	new[32]	_	_
6-9	663-673	expression	abstract[32]	new[32]	_	_
6-10	674-676	of	abstract[32]	new[32]	_	_
6-11	677-679	AD	abstract[32]|abstract|abstract[34]	new[32]|giv|giv[34]	coref	7-1[35_0]
6-12	680-689	pathology	abstract[32]|abstract[34]	new[32]|giv[34]	_	_
6-13	690-691	.	_	_	_	_

#Text=Vascular dementia is more prevalent in men and in populations affected by cerebral small-vessel disease , including Asians , Hispanics , and Africans .
7-1	692-700	Vascular	abstract[35]	giv[35]	coref	7-13[38_35]
7-2	701-709	dementia	abstract[35]	giv[35]	_	_
7-3	710-712	is	_	_	_	_
7-4	713-717	more	_	_	_	_
7-5	718-727	prevalent	_	_	_	_
7-6	728-730	in	_	_	_	_
7-7	731-734	men	person	new	_	_
7-8	735-738	and	_	_	_	_
7-9	739-741	in	_	_	_	_
7-10	742-753	populations	person	new	_	_
7-11	754-762	affected	_	_	_	_
7-12	763-765	by	_	_	_	_
7-13	766-774	cerebral	abstract[38]	giv[38]	coref	15-12[0_38]
7-14	775-787	small-vessel	abstract[38]	giv[38]	_	_
7-15	788-795	disease	abstract[38]	giv[38]	_	_
7-16	796-797	,	abstract[38]	giv[38]	_	_
7-17	798-807	including	abstract[38]	giv[38]	_	_
7-18	808-814	Asians	abstract[38]|person	giv[38]|new	_	_
7-19	815-816	,	abstract[38]	giv[38]	_	_
7-20	817-826	Hispanics	abstract[38]|person	giv[38]|new	_	_
7-21	827-828	,	abstract[38]	giv[38]	_	_
7-22	829-832	and	abstract[38]	giv[38]	_	_
7-23	833-841	Africans	abstract[38]|place	giv[38]|new	_	_
7-24	842-843	.	_	_	_	_

#Text=The cholinergic system is distributed throughout the central nervous system , playing a role in neurotransmission and possibly mediating various neuroprotective functions .
8-1	844-847	The	abstract[42]	new[42]	_	_
8-2	848-859	cholinergic	abstract[42]	new[42]	_	_
8-3	860-866	system	abstract[42]	new[42]	_	_
8-4	867-869	is	_	_	_	_
8-5	870-881	distributed	_	_	_	_
8-6	882-892	throughout	_	_	_	_
8-7	893-896	the	place[43]	new[43]	_	_
8-8	897-904	central	place[43]	new[43]	_	_
8-9	905-912	nervous	place[43]	new[43]	_	_
8-10	913-919	system	place[43]	new[43]	_	_
8-11	920-921	,	_	_	_	_
8-12	922-929	playing	_	_	_	_
8-13	930-931	a	abstract[44]	new[44]	coref	15-3[85_44]
8-14	932-936	role	abstract[44]	new[44]	_	_
8-15	937-939	in	abstract[44]	new[44]	_	_
8-16	940-957	neurotransmission	abstract[44]|abstract	new[44]|new	coref	9-3[47_0]
8-17	958-961	and	_	_	_	_
8-18	962-970	possibly	_	_	_	_
8-19	971-980	mediating	_	_	_	_
8-20	981-988	various	abstract[46]	new[46]	_	_
8-21	989-1004	neuroprotective	abstract[46]	new[46]	_	_
8-22	1005-1014	functions	abstract[46]	new[46]	_	_
8-23	1015-1016	.	_	_	_	_

#Text=Furthermore , cholinergic neurotransmission regulates the immune response during inflammation , in a pathway that involves nicotinic acetylcholine receptors ( nAChRs ) and inhibits peripheral cytokine release .
9-1	1017-1028	Furthermore	_	_	_	_
9-2	1029-1030	,	_	_	_	_
9-3	1031-1042	cholinergic	abstract[47]	giv[47]	_	_
9-4	1043-1060	neurotransmission	abstract[47]	giv[47]	_	_
9-5	1061-1070	regulates	_	_	_	_
9-6	1071-1074	the	abstract[48]	new[48]	_	_
9-7	1075-1081	immune	abstract[48]	new[48]	_	_
9-8	1082-1090	response	abstract[48]	new[48]	_	_
9-9	1091-1097	during	abstract[48]	new[48]	_	_
9-10	1098-1110	inflammation	abstract[48]|abstract[49]	new[48]|new[49]	coref	11-4[0_49]
9-11	1111-1112	,	abstract[48]|abstract[49]	new[48]|new[49]	_	_
9-12	1113-1115	in	abstract[48]|abstract[49]	new[48]|new[49]	_	_
9-13	1116-1117	a	abstract[48]|abstract[49]|abstract[50]	new[48]|new[49]|new[50]	_	_
9-14	1118-1125	pathway	abstract[48]|abstract[49]|abstract[50]	new[48]|new[49]|new[50]	_	_
9-15	1126-1130	that	_	_	_	_
9-16	1131-1139	involves	_	_	_	_
9-17	1140-1149	nicotinic	substance[52]	new[52]	coref	10-19[61_52]
9-18	1150-1163	acetylcholine	abstract|substance[52]	new|new[52]	coref	10-10
9-19	1164-1173	receptors	substance[52]	new[52]	_	_
9-20	1174-1175	(	_	_	_	_
9-21	1176-1182	nAChRs	place	new	_	_
9-22	1183-1184	)	_	_	_	_
9-23	1185-1188	and	_	_	_	_
9-24	1189-1197	inhibits	_	_	_	_
9-25	1198-1208	peripheral	event[55]	new[55]	coref	10-25[62_55]
9-26	1209-1217	cytokine	abstract|event[55]	new|new[55]	_	_
9-27	1218-1225	release	event[55]	new[55]	_	_
9-28	1226-1227	.	_	_	_	_

#Text=In particular , the efferent vagus nerve may release acetylcholine ( Ach ) , which subsequently binds with macrophage receptors and therefore may inhibit the release of inflammatory factors after stroke .
10-1	1228-1230	In	_	_	_	_
10-2	1231-1241	particular	_	_	_	_
10-3	1242-1243	,	_	_	_	_
10-4	1244-1247	the	object[57]	new[57]	_	_
10-5	1248-1256	efferent	object[57]	new[57]	_	_
10-6	1257-1262	vagus	object|object[57]	new|new[57]	_	_
10-7	1263-1268	nerve	object[57]	new[57]	_	_
10-8	1269-1272	may	_	_	_	_
10-9	1273-1280	release	_	_	_	_
10-10	1281-1294	acetylcholine	abstract	giv	appos	10-12
10-11	1295-1296	(	_	_	_	_
10-12	1297-1300	Ach	abstract	giv	coref	17-3
10-13	1301-1302	)	_	_	_	_
10-14	1303-1304	,	_	_	_	_
10-15	1305-1310	which	_	_	_	_
10-16	1311-1323	subsequently	_	_	_	_
10-17	1324-1329	binds	_	_	_	_
10-18	1330-1334	with	_	_	_	_
10-19	1335-1345	macrophage	place|substance[61]	new|giv[61]	_	_
10-20	1346-1355	receptors	substance[61]	giv[61]	_	_
10-21	1356-1359	and	_	_	_	_
10-22	1360-1369	therefore	_	_	_	_
10-23	1370-1373	may	_	_	_	_
10-24	1374-1381	inhibit	_	_	_	_
10-25	1382-1385	the	event[62]	giv[62]	_	_
10-26	1386-1393	release	event[62]	giv[62]	_	_
10-27	1394-1396	of	event[62]	giv[62]	_	_
10-28	1397-1409	inflammatory	event[62]|abstract[63]	giv[62]|new[63]	_	_
10-29	1410-1417	factors	event[62]|abstract[63]	giv[62]|new[63]	_	_
10-30	1418-1423	after	event[62]|abstract[63]	giv[62]|new[63]	_	_
10-31	1424-1430	stroke	event[62]|abstract[63]|event	giv[62]|new[63]|giv	coref	15-10
10-32	1431-1432	.	_	_	_	_

#Text=In addition to inflammation , excitotoxicity and energy failure following cerebral ischemia may also initiate intracellular death pathways and oxidative stress ( OS ) .
11-1	1433-1435	In	_	_	_	_
11-2	1436-1444	addition	_	_	_	_
11-3	1445-1447	to	_	_	_	_
11-4	1448-1460	inflammation	abstract	giv	coref	23-26
11-5	1461-1462	,	_	_	_	_
11-6	1463-1477	excitotoxicity	event	new	_	_
11-7	1478-1481	and	_	_	_	_
11-8	1482-1488	energy	substance|abstract[68]	new|new[68]	_	_
11-9	1489-1496	failure	abstract[68]	new[68]	_	_
11-10	1497-1506	following	_	_	_	_
11-11	1507-1515	cerebral	abstract[69]	new[69]	_	_
11-12	1516-1524	ischemia	abstract[69]	new[69]	_	_
11-13	1525-1528	may	_	_	_	_
11-14	1529-1533	also	_	_	_	_
11-15	1534-1542	initiate	_	_	_	_
11-16	1543-1556	intracellular	abstract[71]	new[71]	_	_
11-17	1557-1562	death	event|abstract[71]	new|new[71]	_	_
11-18	1563-1571	pathways	abstract[71]	new[71]	_	_
11-19	1572-1575	and	_	_	_	_
11-20	1576-1585	oxidative	abstract|abstract[73]	new|new[73]	appos	11-23[0_73]
11-21	1586-1592	stress	abstract[73]	new[73]	_	_
11-22	1593-1594	(	_	_	_	_
11-23	1595-1597	OS	abstract	giv	coref	12-8
11-24	1598-1599	)	_	_	_	_
11-25	1600-1601	.	_	_	_	_

#Text=The structural and functional changes caused by OS led to cholinergic and other cellular damage .
12-1	1602-1605	The	abstract[75]	new[75]	coref	23-36[159_75]
12-2	1606-1616	structural	abstract[75]	new[75]	_	_
12-3	1617-1620	and	abstract[75]	new[75]	_	_
12-4	1621-1631	functional	abstract[75]	new[75]	_	_
12-5	1632-1639	changes	abstract[75]	new[75]	_	_
12-6	1640-1646	caused	_	_	_	_
12-7	1647-1649	by	_	_	_	_
12-8	1650-1652	OS	abstract	giv	coref	14-8
12-9	1653-1656	led	_	_	_	_
12-10	1657-1659	to	_	_	_	_
12-11	1660-1671	cholinergic	abstract[77]	new[77]	coref	22-11[147_77]
12-12	1672-1675	and	abstract[77]	new[77]	_	_
12-13	1676-1681	other	abstract[77]	new[77]	_	_
12-14	1682-1690	cellular	abstract[77]	new[77]	_	_
12-15	1691-1697	damage	abstract[77]	new[77]	_	_
12-16	1698-1699	.	_	_	_	_

#Text=Cholinergic deficit further caused brain atrophy and finally resulted in cognitive impairment .
13-1	1700-1711	Cholinergic	abstract[78]	new[78]	_	_
13-2	1712-1719	deficit	abstract[78]	new[78]	_	_
13-3	1720-1727	further	_	_	_	_
13-4	1728-1734	caused	_	_	_	_
13-5	1735-1740	brain	object|abstract[80]	new|new[80]	_	_
13-6	1741-1748	atrophy	abstract[80]	new[80]	_	_
13-7	1749-1752	and	_	_	_	_
13-8	1753-1760	finally	_	_	_	_
13-9	1761-1769	resulted	abstract	new	coref|none	20-4[130_0]|13-9[0_130]
13-10	1770-1772	in	_	_	_	_
13-11	1773-1782	cognitive	abstract[81]	giv[81]	coref	18-18[112_81]
13-12	1783-1793	impairment	abstract[81]	giv[81]	_	_
13-13	1794-1795	.	_	_	_	_

#Text=Anticholinergic agents have been shown to regulate OS and alleviate apoptosis .
14-1	1796-1811	Anticholinergic	abstract[82]	new[82]	_	_
14-2	1812-1818	agents	abstract[82]	new[82]	_	_
14-3	1819-1823	have	_	_	_	_
14-4	1824-1828	been	_	_	_	_
14-5	1829-1834	shown	_	_	_	_
14-6	1835-1837	to	_	_	_	_
14-7	1838-1846	regulate	_	_	_	_
14-8	1847-1849	OS	abstract	giv	coref	15-17
14-9	1850-1853	and	_	_	_	_
14-10	1854-1863	alleviate	_	_	_	_
14-11	1864-1873	apoptosis	abstract	new	_	_
14-12	1874-1875	.	_	_	_	_

#Text=Therefore , a key role in the pathogenesis of stroke and dementia may be attributed to OS .
15-1	1876-1885	Therefore	_	_	_	_
15-2	1886-1887	,	_	_	_	_
15-3	1888-1889	a	abstract[85]	giv[85]	_	_
15-4	1890-1893	key	abstract[85]	giv[85]	_	_
15-5	1894-1898	role	abstract[85]	giv[85]	_	_
15-6	1899-1901	in	abstract[85]	giv[85]	_	_
15-7	1902-1905	the	abstract[85]|abstract[86]	giv[85]|new[86]	_	_
15-8	1906-1918	pathogenesis	abstract[85]|abstract[86]	giv[85]|new[86]	_	_
15-9	1919-1921	of	abstract[85]|abstract[86]	giv[85]|new[86]	_	_
15-10	1922-1928	stroke	abstract[85]|abstract[86]|event	giv[85]|new[86]|giv	coref	18-23
15-11	1929-1932	and	abstract[85]|abstract[86]	giv[85]|new[86]	_	_
15-12	1933-1941	dementia	abstract[85]|abstract[86]|abstract	giv[85]|new[86]|giv	coref	16-6[91_0]
15-13	1942-1945	may	_	_	_	_
15-14	1946-1948	be	_	_	_	_
15-15	1949-1959	attributed	_	_	_	_
15-16	1960-1962	to	_	_	_	_
15-17	1963-1965	OS	abstract	giv	_	_
15-18	1966-1967	.	_	_	_	_

#Text=Cholinergic dysfunction is related to vascular dementia .
16-1	1968-1979	Cholinergic	abstract[90]	new[90]	coref	20-8[132_90]
16-2	1980-1991	dysfunction	abstract[90]	new[90]	_	_
16-3	1992-1994	is	_	_	_	_
16-4	1995-2002	related	_	_	_	_
16-5	2003-2005	to	_	_	_	_
16-6	2006-2014	vascular	abstract[91]	giv[91]	coref	17-18[97_91]
16-7	2015-2023	dementia	abstract[91]	giv[91]	_	_
16-8	2024-2025	.	_	_	_	_

#Text=Specifically , Ach levels in the cerebrospinal fluid are up to 49 % lower in patients with small-vessel vascular dementia than in control patients , suggesting that cholinergic agents or cholinesterase inhibitors , both of which increase the Ach level , could be used to treat such patients .
17-1	2026-2038	Specifically	_	_	_	_
17-2	2039-2040	,	_	_	_	_
17-3	2041-2044	Ach	abstract|abstract[93]	giv|new[93]	coref|coref	17-39|23-43[163_93]
17-4	2045-2051	levels	abstract[93]	new[93]	_	_
17-5	2052-2054	in	abstract[93]	new[93]	_	_
17-6	2055-2058	the	abstract[93]|object[94]	new[93]|new[94]	_	_
17-7	2059-2072	cerebrospinal	abstract[93]|object[94]	new[93]|new[94]	_	_
17-8	2073-2078	fluid	abstract[93]|object[94]	new[93]|new[94]	_	_
17-9	2079-2082	are	_	_	_	_
17-10	2083-2085	up	_	_	_	_
17-11	2086-2088	to	_	_	_	_
17-12	2089-2091	49	quantity[95]	new[95]	_	_
17-13	2092-2093	%	quantity[95]	new[95]	_	_
17-14	2094-2099	lower	quantity[95]	new[95]	_	_
17-15	2100-2102	in	_	_	_	_
17-16	2103-2111	patients	person[96]	new[96]	_	_
17-17	2112-2116	with	person[96]	new[96]	_	_
17-18	2117-2129	small-vessel	person[96]|abstract[97]	new[96]|giv[97]	coref	21-12[0_97]
17-19	2130-2138	vascular	person[96]|abstract[97]	new[96]|giv[97]	_	_
17-20	2139-2147	dementia	person[96]|abstract[97]	new[96]|giv[97]	_	_
17-21	2148-2152	than	person[96]|abstract[97]	new[96]|giv[97]	_	_
17-22	2153-2155	in	person[96]|abstract[97]	new[96]|giv[97]	_	_
17-23	2156-2163	control	person[96]|abstract[97]|abstract|person[99]	new[96]|giv[97]|new|new[99]	coref	17-47[105_99]
17-24	2164-2172	patients	person[96]|abstract[97]|person[99]	new[96]|giv[97]|new[99]	_	_
17-25	2173-2174	,	_	_	_	_
17-26	2175-2185	suggesting	_	_	_	_
17-27	2186-2190	that	_	_	_	_
17-28	2191-2202	cholinergic	person[100]	new[100]	_	_
17-29	2203-2209	agents	person[100]	new[100]	_	_
17-30	2210-2212	or	_	_	_	_
17-31	2213-2227	cholinesterase	object|object[102]	new|new[102]	coref|coref	21-3[136_102]|23-38[161_0]
17-32	2228-2238	inhibitors	object[102]	new[102]	_	_
17-33	2239-2240	,	_	_	_	_
17-34	2241-2245	both	_	_	_	_
17-35	2246-2248	of	_	_	_	_
17-36	2249-2254	which	_	_	_	_
17-37	2255-2263	increase	_	_	_	_
17-38	2264-2267	the	quantity[104]	new[104]	_	_
17-39	2268-2271	Ach	abstract|quantity[104]	giv|new[104]	coref	22-5
17-40	2272-2277	level	quantity[104]	new[104]	_	_
17-41	2278-2279	,	_	_	_	_
17-42	2280-2285	could	_	_	_	_
17-43	2286-2288	be	_	_	_	_
17-44	2289-2293	used	_	_	_	_
17-45	2294-2296	to	_	_	_	_
17-46	2297-2302	treat	_	_	_	_
17-47	2303-2307	such	person[105]	giv[105]	coref	18-15[111_105]
17-48	2308-2316	patients	person[105]	giv[105]	_	_
17-49	2317-2318	.	_	_	_	_

#Text=One pilot study showed that acetylcholinesterase ( AChE ) inhibitor promoted functional recovery in elderly patients with cognitive impairment who had suffered stroke . In a rat model of chronic ischemic , AChE activity was slightly decreased in the frontal cortex , but muscarinic acetylcholine receptor M1 was gradually depleted in cerebral cortex , striatum and hippocampus that are involved in cognitive function .
18-1	2319-2322	One	abstract[106]	giv[106]	coref	24-14[171_106]
18-2	2323-2328	pilot	abstract[106]	giv[106]	_	_
18-3	2329-2334	study	abstract[106]	giv[106]	_	_
18-4	2335-2341	showed	_	_	_	_
18-5	2342-2346	that	abstract[107]	new[107]	appos	18-8[0_107]
18-6	2347-2367	acetylcholinesterase	abstract[107]	new[107]	_	_
18-7	2368-2369	(	_	_	_	_
18-8	2370-2374	AChE	abstract	giv	coref	18-33
18-9	2375-2376	)	_	_	_	_
18-10	2377-2386	inhibitor	abstract	new	_	_
18-11	2387-2395	promoted	_	_	_	_
18-12	2396-2406	functional	abstract[110]	new[110]	_	_
18-13	2407-2415	recovery	abstract[110]	new[110]	_	_
18-14	2416-2418	in	abstract[110]	new[110]	_	_
18-15	2419-2426	elderly	abstract[110]|person[111]	new[110]|giv[111]	coref	19-5[125_111]
18-16	2427-2435	patients	abstract[110]|person[111]	new[110]|giv[111]	_	_
18-17	2436-2440	with	abstract[110]|person[111]	new[110]|giv[111]	_	_
18-18	2441-2450	cognitive	abstract[110]|person[111]|abstract[112]	new[110]|giv[111]|giv[112]	_	_
18-19	2451-2461	impairment	abstract[110]|person[111]|abstract[112]	new[110]|giv[111]|giv[112]	_	_
18-20	2462-2465	who	_	_	_	_
18-21	2466-2469	had	_	_	_	_
18-22	2470-2478	suffered	_	_	_	_
18-23	2479-2485	stroke	event	giv	coref	19-5
18-24	2486-2487	.	_	_	_	_
18-25	2488-2490	In	_	_	_	_
18-26	2491-2492	a	abstract[115]	new[115]	_	_
18-27	2493-2496	rat	animal|abstract[115]	new|new[115]	_	_
18-28	2497-2502	model	abstract[115]	new[115]	_	_
18-29	2503-2505	of	abstract[115]	new[115]	_	_
18-30	2506-2513	chronic	abstract[115]|object[116]	new[115]|giv[116]	coref	24-32[0_116]
18-31	2514-2522	ischemic	abstract[115]|object[116]	new[115]|giv[116]	_	_
18-32	2523-2524	,	_	_	_	_
18-33	2525-2529	AChE	place|abstract[118]	giv|new[118]	coref|coref	19-9|19-8[127_118]
18-34	2530-2538	activity	abstract[118]	new[118]	_	_
18-35	2539-2542	was	_	_	_	_
18-36	2543-2551	slightly	_	_	_	_
18-37	2552-2561	decreased	_	_	_	_
18-38	2562-2564	in	_	_	_	_
18-39	2565-2568	the	object[119]	new[119]	coref	18-52[121_119]
18-40	2569-2576	frontal	object[119]	new[119]	_	_
18-41	2577-2583	cortex	object[119]	new[119]	_	_
18-42	2584-2585	,	_	_	_	_
18-43	2586-2589	but	_	_	_	_
18-44	2590-2600	muscarinic	object[120]	new[120]	_	_
18-45	2601-2614	acetylcholine	object[120]	new[120]	_	_
18-46	2615-2623	receptor	object[120]	new[120]	_	_
18-47	2624-2626	M1	object[120]	new[120]	_	_
18-48	2627-2630	was	_	_	_	_
18-49	2631-2640	gradually	_	_	_	_
18-50	2641-2649	depleted	_	_	_	_
18-51	2650-2652	in	_	_	_	_
18-52	2653-2661	cerebral	object[121]	giv[121]	_	_
18-53	2662-2668	cortex	object[121]	giv[121]	_	_
18-54	2669-2670	,	_	_	_	_
18-55	2671-2679	striatum	_	_	_	_
18-56	2680-2683	and	_	_	_	_
18-57	2684-2695	hippocampus	object	new	_	_
18-58	2696-2700	that	_	_	_	_
18-59	2701-2704	are	_	_	_	_
18-60	2705-2713	involved	_	_	_	_
18-61	2714-2716	in	_	_	_	_
18-62	2717-2726	cognitive	abstract[123]	new[123]	coref	22-7[145_123]
18-63	2727-2735	function	abstract[123]	new[123]	_	_
18-64	2736-2737	.	_	_	_	_

#Text=In addition , in stroke patients , reduced AChE activity was correlated with lower survival rate .
19-1	2738-2740	In	_	_	_	_
19-2	2741-2749	addition	_	_	_	_
19-3	2750-2751	,	_	_	_	_
19-4	2752-2754	in	_	_	_	_
19-5	2755-2761	stroke	event|person[125]	giv|giv[125]	coref|coref	20-14|21-12[141_125]
19-6	2762-2770	patients	person[125]	giv[125]	_	_
19-7	2771-2772	,	_	_	_	_
19-8	2773-2780	reduced	abstract[127]	giv[127]	coref	23-45[164_127]
19-9	2781-2785	AChE	abstract|abstract[127]	giv|giv[127]	coref	20-8
19-10	2786-2794	activity	abstract[127]	giv[127]	_	_
19-11	2795-2798	was	_	_	_	_
19-12	2799-2809	correlated	_	_	_	_
19-13	2810-2814	with	_	_	_	_
19-14	2815-2820	lower	abstract[129]	new[129]	_	_
19-15	2821-2829	survival	event|abstract[129]	new|new[129]	_	_
19-16	2830-2834	rate	abstract[129]	new[129]	_	_
19-17	2835-2836	.	_	_	_	_

#Text=Taken together , these results suggest that AChE dysfunction is a result of stroke rather than a cause for further neurodegeneration .
20-1	2837-2842	Taken	_	_	_	_
20-2	2843-2851	together	_	_	_	_
20-3	2852-2853	,	_	_	_	_
20-4	2854-2859	these	abstract[130]	new[130]	_	_
20-5	2860-2867	results	abstract[130]	new[130]	_	_
20-6	2868-2875	suggest	_	_	_	_
20-7	2876-2880	that	_	_	_	_
20-8	2881-2885	AChE	abstract|abstract[132]	giv|giv[132]	coref	22-7
20-9	2886-2897	dysfunction	abstract[132]	giv[132]	_	_
20-10	2898-2900	is	_	_	_	_
20-11	2901-2902	a	_	_	_	_
20-12	2903-2909	result	_	_	_	_
20-13	2910-2912	of	_	_	_	_
20-14	2913-2919	stroke	event	giv	coref	21-9
20-15	2920-2926	rather	_	_	_	_
20-16	2927-2931	than	_	_	_	_
20-17	2932-2933	a	abstract[134]	giv[134]	_	_
20-18	2934-2939	cause	abstract[134]	giv[134]	_	_
20-19	2940-2943	for	abstract[134]	giv[134]	_	_
20-20	2944-2951	further	abstract[134]|abstract[135]	giv[134]|new[135]	_	_
20-21	2952-2969	neurodegeneration	abstract[134]|abstract[135]	giv[134]|new[135]	_	_
20-22	2970-2971	.	_	_	_	_

#Text=Moreover , AChE inhibitors exert no effect on stroke risk in dementia patients .
21-1	2972-2980	Moreover	_	_	_	_
21-2	2981-2982	,	_	_	_	_
21-3	2983-2987	AChE	object[136]	giv[136]	_	_
21-4	2988-2998	inhibitors	object[136]	giv[136]	_	_
21-5	2999-3004	exert	_	_	_	_
21-6	3005-3007	no	abstract[137]	new[137]	_	_
21-7	3008-3014	effect	abstract[137]	new[137]	_	_
21-8	3015-3017	on	abstract[137]	new[137]	_	_
21-9	3018-3024	stroke	abstract[137]|event|abstract[139]	new[137]|giv|giv[139]	coref	24-31[177_0]
21-10	3025-3029	risk	abstract[137]|abstract[139]	new[137]|giv[139]	_	_
21-11	3030-3032	in	abstract[137]|abstract[139]	new[137]|giv[139]	_	_
21-12	3033-3041	dementia	abstract[137]|abstract[139]|abstract|person[141]	new[137]|giv[139]|giv|giv[141]	coref	23-47[165_141]
21-13	3042-3050	patients	abstract[137]|abstract[139]|person[141]	new[137]|giv[139]|giv[141]	_	_
21-14	3051-3052	.	_	_	_	_

#Text=These observations suggest that Ach and AChE function may predict post-stroke neuronal damage .
22-1	3053-3058	These	abstract[142]	new[142]	_	_
22-2	3059-3071	observations	abstract[142]	new[142]	_	_
22-3	3072-3079	suggest	_	_	_	_
22-4	3080-3084	that	_	_	_	_
22-5	3085-3088	Ach	abstract	giv	coref	24-2[168_0]
22-6	3089-3092	and	_	_	_	_
22-7	3093-3097	AChE	organization|abstract[145]	giv|giv[145]	coref	24-7
22-8	3098-3106	function	abstract[145]	giv[145]	_	_
22-9	3107-3110	may	_	_	_	_
22-10	3111-3118	predict	_	_	_	_
22-11	3119-3130	post-stroke	abstract[147]	giv[147]	_	_
22-12	3131-3139	neuronal	person|abstract[147]	new|giv[147]	_	_
22-13	3140-3146	damage	abstract[147]	giv[147]	_	_
22-14	3147-3148	.	_	_	_	_

#Text=To date , only a few blood biomarkers for predicting PSD have been examined ( e. g. , D-amino acid oxidase , β-secretase , and inflammation markers ) , and few studies have focused on changes in blood cholinesterase ( ChE ) levels and activity in patients with PSD .
23-1	3149-3151	To	_	_	_	_
23-2	3152-3156	date	time	new	_	_
23-3	3157-3158	,	_	_	_	_
23-4	3159-3163	only	abstract[150]	new[150]	_	_
23-5	3164-3165	a	abstract[150]	new[150]	_	_
23-6	3166-3169	few	abstract[150]	new[150]	_	_
23-7	3170-3175	blood	substance|abstract[150]	new|new[150]	coref	23-38
23-8	3176-3186	biomarkers	abstract[150]	new[150]	_	_
23-9	3187-3190	for	_	_	_	_
23-10	3191-3201	predicting	_	_	_	_
23-11	3202-3205	PSD	abstract	new	_	_
23-12	3206-3210	have	_	_	_	_
23-13	3211-3215	been	_	_	_	_
23-14	3216-3224	examined	_	_	_	_
23-15	3225-3226	(	_	_	_	_
23-16	3227-3229	e.	_	_	_	_
23-17	3230-3232	g.	_	_	_	_
23-18	3233-3234	,	_	_	_	_
23-19	3235-3242	D-amino	object	new	_	_
23-20	3243-3247	acid	substance|abstract[154]	new|new[154]	_	_
23-21	3248-3255	oxidase	abstract[154]	new[154]	_	_
23-22	3256-3257	,	_	_	_	_
23-23	3258-3269	β-secretase	substance	new	_	_
23-24	3270-3271	,	_	_	_	_
23-25	3272-3275	and	_	_	_	_
23-26	3276-3288	inflammation	abstract|abstract[157]	giv|new[157]	_	_
23-27	3289-3296	markers	abstract[157]	new[157]	_	_
23-28	3297-3298	)	_	_	_	_
23-29	3299-3300	,	_	_	_	_
23-30	3301-3304	and	_	_	_	_
23-31	3305-3308	few	event[158]	giv[158]	_	_
23-32	3309-3316	studies	event[158]	giv[158]	_	_
23-33	3317-3321	have	_	_	_	_
23-34	3322-3329	focused	_	_	_	_
23-35	3330-3332	on	_	_	_	_
23-36	3333-3340	changes	abstract[159]	giv[159]	_	_
23-37	3341-3343	in	abstract[159]	giv[159]	_	_
23-38	3344-3349	blood	abstract[159]|substance|abstract[161]	giv[159]|giv|giv[161]	appos	23-41[0_161]
23-39	3350-3364	cholinesterase	abstract[159]|abstract[161]	giv[159]|giv[161]	_	_
23-40	3365-3366	(	_	_	_	_
23-41	3367-3370	ChE	abstract	giv	_	_
23-42	3371-3372	)	_	_	_	_
23-43	3373-3379	levels	abstract[163]	giv[163]	_	_
23-44	3380-3383	and	abstract[163]	giv[163]	_	_
23-45	3384-3392	activity	abstract[163]|abstract[164]	giv[163]|giv[164]	_	_
23-46	3393-3395	in	abstract[163]|abstract[164]	giv[163]|giv[164]	_	_
23-47	3396-3404	patients	abstract[163]|abstract[164]|person[165]	giv[163]|giv[164]|giv[165]	coref	24-29[175_165]
23-48	3405-3409	with	abstract[163]|abstract[164]|person[165]	giv[163]|giv[164]|giv[165]	_	_
23-49	3410-3413	PSD	abstract[163]|abstract[164]|person[165]|abstract	giv[163]|giv[164]|giv[165]|new	_	_
23-50	3414-3415	.	_	_	_	_

#Text=Since plasma Ach is metabolized by AChE and butylcholinesterase ( BChE ) , the present study examined the functional activities of these two enzymes in a population of patients with chronic ischemic stroke ( IS ) .
24-1	3416-3421	Since	_	_	_	_
24-2	3422-3428	plasma	abstract|abstract[168]	new|giv[168]	_	_
24-3	3429-3432	Ach	abstract[168]	giv[168]	_	_
24-4	3433-3435	is	_	_	_	_
24-5	3436-3447	metabolized	_	_	_	_
24-6	3448-3450	by	_	_	_	_
24-7	3451-3455	AChE	substance	giv	_	_
24-8	3456-3459	and	_	_	_	_
24-9	3460-3479	butylcholinesterase	_	_	_	_
24-10	3480-3481	(	_	_	_	_
24-11	3482-3486	BChE	object	new	_	_
24-12	3487-3488	)	_	_	_	_
24-13	3489-3490	,	_	_	_	_
24-14	3491-3494	the	abstract[171]	giv[171]	_	_
24-15	3495-3502	present	abstract[171]	giv[171]	_	_
24-16	3503-3508	study	abstract[171]	giv[171]	_	_
24-17	3509-3517	examined	_	_	_	_
24-18	3518-3521	the	abstract[172]	new[172]	_	_
24-19	3522-3532	functional	abstract[172]	new[172]	_	_
24-20	3533-3543	activities	abstract[172]	new[172]	_	_
24-21	3544-3546	of	abstract[172]	new[172]	_	_
24-22	3547-3552	these	abstract[172]|substance[173]	new[172]|new[173]	_	_
24-23	3553-3556	two	abstract[172]|substance[173]	new[172]|new[173]	_	_
24-24	3557-3564	enzymes	abstract[172]|substance[173]	new[172]|new[173]	_	_
24-25	3565-3567	in	abstract[172]|substance[173]	new[172]|new[173]	_	_
24-26	3568-3569	a	abstract[172]|substance[173]|abstract[174]	new[172]|new[173]|new[174]	_	_
24-27	3570-3580	population	abstract[172]|substance[173]|abstract[174]	new[172]|new[173]|new[174]	_	_
24-28	3581-3583	of	abstract[172]|substance[173]|abstract[174]	new[172]|new[173]|new[174]	_	_
24-29	3584-3592	patients	abstract[172]|substance[173]|abstract[174]|person[175]	new[172]|new[173]|new[174]|giv[175]	_	_
24-30	3593-3597	with	abstract[172]|substance[173]|abstract[174]|person[175]	new[172]|new[173]|new[174]|giv[175]	_	_
24-31	3598-3605	chronic	abstract[172]|substance[173]|abstract[174]|person[175]|event[177]	new[172]|new[173]|new[174]|giv[175]|giv[177]	_	_
24-32	3606-3614	ischemic	abstract[172]|substance[173]|abstract[174]|person[175]|object|event[177]	new[172]|new[173]|new[174]|giv[175]|giv|giv[177]	_	_
24-33	3615-3621	stroke	abstract[172]|substance[173]|abstract[174]|person[175]|event[177]	new[172]|new[173]|new[174]|giv[175]|giv[177]	_	_
24-34	3622-3623	(	_	_	_	_
24-35	3624-3626	IS	abstract	new	_	_
24-36	3627-3628	)	_	_	_	_
24-37	3629-3630	.	_	_	_	_
